Can mupirocin prevent methicillin-resistant Staphylococcus aureus infections?
In a retrospective study, Dr Muller and colleagues have assessed the efficacy of mupirocin nasal ointment alongside hygienic measures in methicillin-resistant Staphylococcus aureus (MRSA)-positive patients admitted to the intensive care unit (ICU). Their findings, which suggest that intranasal mupirocin can prevent ICU-related MRSA infections, need confirmation in a well-designed clinical trial. In general: early identification, isolation and treatment of all MRSA carriers, including health care workers, and disinfection of contaminated environments, are the main 'ingredients' of an effective MRSA 'search and destroy' program.
|Keywords||*Methicillin Resistance, Administration, Intranasal, Anti-Bacterial Agents/administration & dosage/*therapeutic use, Cross Infection/*prevention & control, Humans, Intensive Care Units, Mupirocin/administration & dosage/*therapeutic use, Staphylococcal Infections/*prevention & control|
|Persistent URL||dx.doi.org/10.1186/cc3720, hdl.handle.net/1765/17743|
Wertheim, H.F.L., & Vos, M.C.. (2005). Can mupirocin prevent methicillin-resistant Staphylococcus aureus infections?. Critical Care (Print), 9(3), 257–258. doi:10.1186/cc3720